Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Creon® (Pancrelipase) Delayed-Release Capsules First and Only Pancreatic Enzyme Product to Receive FDA Approval Under New Guidelines
May 27th, 2009
Solvay Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved CREON® (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) or other conditions. CREON® is the first and only pancreatic enzyme product (PEP) to receive FDA approval under new guidelines for the class. "Left untreated, EPI causes maldigestion, malabsorption and malnutrition and can ultimately be life-threatening," said Virginia Stallings, M.D., Director, Nutrition Center at the Children's Hospital of Philadelphia, PA and Professor of Pediatrics, University of Pennsylvania School of Medicine. "The...
Source: Vaccine Weekly (2009-05-27)
|
